Ind Swift Laboratories Limited

BSE: 532305 NSE: INDSWFTLAB
Ind Swift Laboratories Limited - pharma in Chandigarh, India. FY 2026 financials & compliance.
CIN L24232CH1995PLC015553 Incorporated 04 January 1995 ROC Chandigarh HQ Chandigarh, India
Active Listed - NSE: INDSWFTLAB · BSE: 532305 Public Limited Company pharma
Data last updated
Market Cap
₹3,003 Cr
INDSWFTLAB · NSE
Share Price
₹331.15
-4.11% today
Revenue
₹641 Cr
FY 2025-26 · +14.2% YoY
EBITDA
₹34.09 Cr
Margin 5.3%
Net Profit
₹49.48 Cr
FY 2025-26 · +2695.5% YoY
P/E (TTM)
47.0x
P/B 2.2x
Authorised capital
₹140 Cr
Registered with MCA
Paid-up capital
₹86.96 Cr
Issued & subscribed

About Ind Swift Laboratories Limited

Data last updated:

Ind Swift Laboratories Limited is a public limited company based in Chandigarh, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 04 January 1995 and has been in existence for over 31 years.

The company is registered with the Registrar of Companies (ROC), Chandigarh, under CIN L24232CH1995PLC015553. Its GSTIN is 04AAACI6306G1Z1 (Chandigarh). The company holds 17 GST registrations, of which 15 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 532305 and NSE: INDSWFTLAB.

The company has an authorised share capital of ₹140 Cr and a paid-up capital of ₹86.96 Cr. It is led by directors including Navrattan Munjal (Managing Director) and Rishav Mehta (Whole-Time Director).

Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at SCO 850 Shivalik Enclave Nac Manimajra, Chandigarh, India – 160101.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹641.29 Cr, a growth of 14.2% compared to the previous year. For the same year it recorded a net profit of ₹49.48 Cr (net margin 7.7%) and EBITDA of ₹34.09 Cr (EBITDA margin 5.3%). The net worth stands at ₹1,384.03 Cr (up 16.6% YoY). Total assets are valued at ₹1,421.67 Cr (up 16.1% YoY).

Its group structure includes 2 subsidiaries.

The company is associated with 1 brand: Ind Swift. As per MCA filings, the company has open charges of ₹827.92 Cr and satisfied charges of ₹5,103.76 Cr on record. Court records list 354 cases involving the company, including 87 filed by the company and 268 filed against it; 23 cases are pending. The company has 125 deals on record (110 market trades, 11 funding rounds, 3 convertible or debt financings), with disclosed funding of ₹260.65 Cr; the latest was in May 2026. Its 9 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 5 smaller; the largest is Anuh Pharma Limited with revenue of ₹670.97 Cr.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website indswiftlabs.com.

Company details

CIN L24232CH1995PLC015553
Registration Number 015553
Incorporation Date 04 January 1995
ROC Chandigarh
Listing Status Listed - Listed on NSE (INDSWFTLAB); Listed on BSE (532305)
Company Status Active
Date of Last AGM 29 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

CIN history

Ind Swift Laboratories has one previous CIN (Corporate Identification Number): U24232CH1995PLC015553. The current CIN is L24232CH1995PLC015553, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24232CH1995PLC015553Current
U24232CH1995PLC015553Previous
Key People
Navrattan Munjal Managing Director Rishav Mehta Whole-Time Director Himanshu Jain Whole-Time Director

Contact details

Ind Swift Laboratories Limited's registered office is in Chandigarh, Chandigarh. Its website is indswiftlabs.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    indswiftlabs.com
  • Social Media
  • Registered Address
    SCO 850 Shivalik Enclave Nac Manimajra, Chandigarh, India – 160101
  • Industry
    Pharma, API Manufacturers

To see the full contact details of Ind Swift Laboratories Limited, buy the company report.

Comprehensive company report
Ind Swift Laboratories Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Ind Swift Laboratories operates one associated brand: Ind Swift. Each brand links to its own profile.

BrandDescriptionWebsite
Ind Swift
API CDMO also having capabilities to manufacture HPAPIs and intermediatesindswiftlabs.com

Business activity

The main business activity of Ind Swift Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Ind Swift Laboratories Limited, buy the company report.

Financials of Ind Swift Laboratories Limited

FY 2025-26 filings available

Ind Swift Laboratories Limited reported revenue of ₹641.29 Cr (up 14.2% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹641 Cr
+14.2% YoY
EBITDA
₹34.09 Cr
+275.8% YoY
Profit After Tax
₹49.48 Cr
+2695.5% YoY
Net Worth
₹1,384 Cr
+16.6% YoY
Total Assets
₹1,422 Cr
+16.1% YoY
Total Debt
₹17.91 Cr
-4.6% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue6415621,2811,2071,039891780
Revenue growth+14.2%-56.2%+6.1%+16.2%+16.5%+14.3%-
EBITDA34.09(19.39)254203196183144
EBITDA margin+5.3%-3.5%+19.9%+16.8%+18.8%+20.5%+18.5%
Profit before tax49.0525858286.5212.5318.01(19.77)
Net profit49.481.7714061.511.30(3.15)(21.26)
Net profit margin+7.7%+0.3%+11.0%+5.1%+0.1%-0.4%-2.7%
EPS (₹)4.8436.4471.247.96(0.36)(0.53)(3.54)
Balance sheet
Total assets1,4221,2259491,5621,5711,6251,687
Net worth1,3841,187931682601604641
Total debt17.9118.7816.638629531,0051,031
Cash & bank43042543218.2021.4811.6010.58
Net working capital713612445902846750680
Cash flow
Cash from operations(68.17)(28.69)(163)195150135125
Cash from investing(68.90)(113)(104)(13.37)4.77(10.17)(9.10)
Cash from financing14272.42699(186)(141)(124)(133)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue19117015115315313812911.96
Revenue growth (YoY)+25.4%+22.8%+17.1%+1176.3%+360.5%---
Other income7.652.2227.5817.8614.5822016.6413.01
EBITDA33.1915.42(1.68)1.473.60(9.19)(7.37)(11.79)
EBITDA margin+17.3%+9.1%-1.1%+1.0%+2.4%-6.6%-5.7%-98.6%
Depreciation7.588.128.846.986.687.445.810.22
Interest0.71(2.43)0.672.011.15(26.76)10.030.41
Profit before tax32.5511.9516.3910.3410.35230(6.57)0.59
Tax7.99(3.15)6.872.301.718.19(1.08)0.18
Net profit24.5615.109.528.048.64222(5.49)0.41
EPS (₹)2.841.761.130.961.1730.08(0.82)0.07
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue6365501,6731,152988857752
Revenue growth+15.7%-67.1%+45.2%+16.6%+15.4%+13.9%-
EBITDA35.23(12.94)299195192180142
EBITDA margin+5.5%-2.4%+17.9%+17.0%+19.4%+21.1%+18.9%
Profit before tax50.2226459479.198.0016.12(19.57)
Net profit50.708.0514655.86(2.57)(4.40)(20.87)
Net profit margin+8.0%+1.5%+8.7%+4.9%-0.3%-0.5%-2.8%
EPS (₹)4.9737.2579.777.10(0.95)(0.74)(3.48)
Balance sheet
Total assets1,4081,2121,0281,5471,5941,6511,691
Net worth1,3711,178812675633639645
Total debt17.9115.332008549449961,031
Cash & bank4154104889.969.389.958.84
Net working capital617545472833789700675
Cash flow
Cash from operations(40.19)(45.30)(166)183136135123
Cash from investing(100)(110)(27.71)(13.69)2.76(10.17)(10.15)
Cash from financing14577.44658(168)(140)(124)(133)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1861731531501481501222.71
Revenue growth (YoY)+25.7%+15.5%+26.0%+5451.3%+385.9%---
Other income7.632.2123.8917.8614.5821616.6312.95
Total expenses15315815014814515812314.71
EBITDA33.0915.153.232.193.07(8.69)(1.66)(12.00)
EBITDA margin+17.8%+8.8%+2.1%+1.5%+2.1%-5.8%-1.4%-442.8%
Depreciation7.588.088.846.986.687.445.810.22
Interest0.71(2.44)0.672.011.15(26.76)10.030.41
Profit before tax32.4311.7217.6111.069.82226(0.87)0.32
Tax7.98(3.22)6.872.301.718.050.000.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 23 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue19117015115315313812911.96
Revenue growth (YoY)+25.4%+22.8%+17.1%+1176.3%+360.5%---
Other income7.652.2227.5817.8614.5822016.6413.01
EBITDA33.1915.42(1.68)1.473.60(9.19)(7.37)(11.79)
EBITDA margin+17.3%+9.1%-1.1%+1.0%+2.4%-6.6%-5.7%-98.6%
Depreciation7.588.128.846.986.687.445.810.22
Interest0.71(2.43)0.672.011.15(26.76)10.030.41
Profit before tax32.5511.9516.3910.3410.35230(6.57)0.59
Tax7.99(3.15)6.872.301.718.19(1.08)0.18
Net profit24.5615.109.528.048.64222(5.49)0.41
EPS (₹)2.841.761.130.961.1730.08(0.82)0.07
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue6415621,2811,2071,039891780
Revenue growth+14.2%-56.2%+6.1%+16.2%+16.5%+14.3%-
Other income46.9730543233.5043.5022.7033.40
Total expenses6075811,0271,005843709635
Employee cost0.00118153136127107103
EBITDA34.09(19.39)254203196183144
EBITDA margin+5.3%-3.5%+19.9%+16.8%+18.8%+20.5%+18.5%
Depreciation30.6124.4853.3057.3613187.2990.06
Interest1.402.9251.1092.1795.55100107
Profit before tax49.0525858286.5212.5318.01(19.77)
Tax7.737.2716038.6914.6821.161.42
Net profit49.481.7714061.511.30(3.15)(21.26)
Net profit margin+7.7%+0.3%+11.0%+5.1%+0.1%-0.4%-2.7%
EPS (₹)4.8436.4471.247.96(0.36)(0.53)(3.54)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital86.8482.9459.0959.8159.8159.8159.81
Reserves & surplus1,2971,030872622541544581
Shareholders' funds (net worth)1,3841,187931682601604641
Minority interest(0.06)(0.03)(0.02)0.00(0.11)(0.09)0.00
Secured loans9.314.698.17796906972973
Unsecured loans8.6014.098.4665.7746.9933.1057.97
Total debt17.9118.7816.638629531,0051,031
Total liabilities1,4221,2259491,5621,5711,6251,687
Assets
Gross block70065511.021,3341,3221,3171,357
Net block3042737.66587630753843
Capital work in progress12.410.000.007.7110.3118.8411.45
Investments24821311130.3429.0635.5317.45
Inventories14811410.46439428376343
Sundry debtors199165169505455432396
Cash & bank balances43042543218.2021.4811.6010.58
Loans & advances18912249.62202171125113
Total current assets9658266611,1651,075944863
Total current liabilities252214216262230194183
Net working capital713612445902846750680
Total assets1,4221,2259491,5621,5711,6251,687
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash42549418.2021.4811.6010.5829.97
Net cash from operating activities(68.17)(28.69)(163)195150135125
Net cash from investing activities(68.90)(113)(104)(13.37)4.77(10.17)(9.10)
Net cash from financing activities14272.42699(186)(141)(124)(133)
Net change in cash4.74(68.82)431(4.41)14.171.03(17.12)
Closing cash43042543218.2021.4811.6010.58
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+14.2%-56.2%+6.1%+16.2%+16.5%+14.3%-
EBITDA growth+275.8%-107.6%+25.5%+3.5%+7.0%+26.6%-
PBT growth-81.0%-55.7%+572.4%+590.5%-30.4%+9998.0%-
Net income growth+2695.5%-98.7%+128.4%+4631.5%+141.3%+85.2%-
Revenue CAGR (3Y)-19.0%-18.5%+12.9%+15.7%+11.1%+5.2%+2.9%
EBITDA CAGR (3Y)-44.8%-+11.6%+12.0%+15.8%+11.4%+13.0%
Profitability & leverage
Net income margin+6.4%+44.6%+32.9%+4.0%-0.2%-0.4%-2.7%
Return on capital employed-+0.8%+20.7%+14.8%0.0%0.0%0.0%
Return on net worth-+0.2%+19.3%+13.2%0.0%0.0%0.0%
Debt / equity-0.020.612.012.462.522.85
Long-term debt / equity-0.010.531.772.172.202.43
Interest cover40.23-6.6625.4363.48147.96104.91197.88
Efficiency & per share
Fixed asset turnover-1.692.201.060.930.800.68
Inventory turnover-9.015.702.782.582.482.36
Debtors turnover-3.373.802.512.342.152.09
EPS (₹)4.8436.4471.247.96(0.36)(0.53)(3.54)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.00159.86157.6483.3667.6365.6769.49
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1861731531501481501222.71
Revenue growth (YoY)+25.7%+15.5%+26.0%+5451.3%+385.9%---
Other income7.632.2123.8917.8614.5821616.6312.95
Total expenses15315815014814515812314.71
EBITDA33.0915.153.232.193.07(8.69)(1.66)(12.00)
EBITDA margin+17.8%+8.8%+2.1%+1.5%+2.1%-5.8%-1.4%-442.8%
Depreciation7.588.088.846.986.687.445.810.22
Interest0.71(2.44)0.672.011.15(26.76)10.030.41
Profit before tax32.4311.7217.6111.069.82226(0.87)0.32
Tax7.98(3.22)6.872.301.718.050.000.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue6365501,6731,152988857752
Revenue growth+15.7%-67.1%+45.2%+16.6%+15.4%+13.9%-
Other income46.9630447933.2842.5023.1336.02
Total expenses6015631,374957796676610
Employee cost0.00115233133125104100
EBITDA35.23(12.94)299195192180142
EBITDA margin+5.5%-2.4%+17.9%+17.0%+19.4%+21.1%+18.9%
Depreciation30.5724.4880.4157.3613187.2990.06
Interest1.402.9210492.1795.55100107
Profit before tax50.2226459479.198.0016.12(19.57)
Tax7.668.0557.7636.7213.7020.521.23
Net profit50.708.0514655.86(2.57)(4.40)(20.87)
Net profit margin+8.0%+1.5%+8.7%+4.9%-0.3%-0.5%-2.8%
EPS (₹)4.9737.2579.777.10(0.95)(0.74)(3.48)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital86.8482.9481.4159.8159.8159.8159.81
Reserves & surplus1,2841,021731616573579585
Shareholders' funds (net worth)1,3711,178812675633639645
Secured loans9.314.694.87839929964973
Unsecured loans8.6010.6419514.3414.8832.9457.97
Total debt17.9115.332008549449961,031
Total liabilities1,4081,2121,0281,5471,5941,6511,691
Assets
Gross block6996555631,3331,3191,3161,356
Net block304273192587629752843
Capital work in progress12.410.0051.247.7110.3118.8411.45
Investments33026916785.1211155.3326.36
Inventories14310764.09428414354343
Sundry debtors189160259469428400385
Cash & bank balances4154104889.969.389.958.84
Loans & advances11676.8041.71167146101108
Total current assets8637548521,074998866845
Total current liabilities246210380241209166169
Net working capital617545472833789700675
Total assets1,4081,2121,0281,5471,5941,6511,691
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash41048823.289.389.958.8429.09
Net cash from operating activities(40.19)(45.30)(166)183136135123
Net cash from investing activities(100)(110)(27.71)(13.69)2.76(10.17)(10.15)
Net cash from financing activities14577.44658(168)(140)(124)(133)
Net change in cash4.90(77.53)4640.58(0.57)1.11(20.25)
Closing cash4154104889.969.389.958.84
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+15.7%-67.1%+45.2%+16.6%+15.4%+13.9%-
EBITDA growth+372.3%-104.3%+52.9%+1.8%+6.4%+27.2%-
PBT growth-81.0%-55.5%+650.0%+889.9%-50.4%+9998.0%-
Net income growth+529.8%-94.5%+161.7%+2273.5%+41.6%+78.9%-
Revenue CAGR (3Y)-18.0%-17.8%+25.0%+15.3%+10.9%+5.4%+2.7%
EBITDA CAGR (3Y)-43.5%-+18.3%+11.3%+15.3%+13.0%+12.7%
Profitability & leverage
Net income margin+6.7%+46.6%+32.1%+3.7%-0.6%-0.5%-2.8%
Return on capital employed-+1.1%+18.8%+14.2%0.0%0.0%0.0%
Return on net worth-+0.6%+16.9%+11.6%0.0%0.0%0.0%
Debt / equity-0.110.811.942.252.392.83
Long-term debt / equity-0.100.711.711.992.092.41
Interest cover30.04-7.8047.5166.75156.51107.52207.13
Efficiency & per share
Fixed asset turnover-0.901.951.010.890.770.66
Inventory turnover-6.426.802.742.572.462.28
Debtors turnover-2.624.592.572.392.182.09
EPS (₹)4.9737.2579.777.10(0.95)(0.74)(3.48)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.00158.56118.7582.2672.9171.5570.15

To see the full year-wise statements and ratios of Ind Swift Laboratories Limited, buy the company report.

Board of directors of Ind Swift Laboratories Limited

Ind Swift Laboratories has 8 current directors and 26 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Rishav Mehta
Also directs: Essix Biosciences Limited, Vibrant Agro Industries Limited
Whole-Time Director23 Mar 201016 Years 7 MonthsCurrent
Himanshu Jain
Also directs: Indis Healthcare LLP, Capital Strikers LLP, MJM Remedies Private Limited and 2 more
Whole-Time Director04 Jan 199531 Years 9 MonthsCurrent
Sahil Munjal
Also directs: Fortune (India) Constructions Limited, Vibrant Agro Industries Limited, Punjab Renewable Energy Private Limited
Whole-Time Director13 Feb 20206 Years 8 MonthsCurrent
Neerja ChathleyDirector10 May 20197 Years 5 MonthsCurrent
Rajinder Kumar Gupta
Also directs: M S Construction Enterprises LLP
Director23 Jun 20215 Years 4 MonthsCurrent
Navrattan Munjal
Also directs: MJM Remedies Private Limited, Essix Biosciences Limited, Nimbua Greenfield (Punjab) Association and 1 more
Managing Director04 Jan 199531 Years 9 MonthsCurrent
Showing 6 of 8 current directors. View all directors

Peer comparison

Ind Swift Laboratories Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Anuh Pharma Limited₹670.97 Cr (FY 2025)2.0%Mumbai, Maharashtra, India
RPG Life Sciences Limited₹666.11 Cr (FY 2025)13.0%Mumbai, Maharashtra, India
Ami Lifesciences Pvt Ltd₹659.86 Cr (FY 2025)20.0%Vadodara, Gujarat, India
Nosch Labs Private Limited₹643.87 Cr (FY 2025)5.0%Hyderabad, Telangana, India
Amoli Organics Private Limited₹641.59 Cr (FY 2022)7.0%Valsad, Gujarat, India
Ind Swift Laboratories Limitedthis company₹641.29 Cr (FY 2026)₹49.48 Cr7.7%14.2%Chandigarh, India
Malladi Drugs and Pharmaceuticals Limited₹626.79 Cr (FY 2025)-7.0%Chennai, Tamil Nadu, India
Ra Chem Pharma Limited₹621.32 Cr (FY 2021)15.0%Hyderabad, Telangana, India
Wanbury Limited₹603.01 Cr (FY 2025)4.0%Navi Mumbai, Maharashtra, India
Global Calcium Private Limited₹594.12 Cr (FY 2025)2.0%Hosur, Tamil Nadu, India

To see the full peer comparison of Ind Swift Laboratories Limited, buy the company report.

Auditor

Ind Swift Laboratories Limited is audited by Avishkar Singhal & Associates for the financial year 2024.

Auditor firmFinancial yearFirm registration number
Avishkar Singhal & AssociatesFY 2024017362N

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 42.90%, foreign institutional investors hold 10.70%, domestic institutional investors hold 0.20% and retail and other public shareholders hold 46.20%.

Promoters: 42.90%DII (Domestic Institutional): 0.20%FII (Foreign Institutional): 10.70%Retail & Others: 46.20%
Sep 2026
QUARTER
42.90% Promoters
0.20% DII (Domestic Institutional)
10.70% FII (Foreign Institutional)
46.20% Retail & Others
Promoter holding - history
Now 42.90% · Sep 2026High 43.00% · Jun 2026Low 39.50% · Dec 2025
38%39.5%41%42.5%44%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 39.50%Mar 2026: 39.50%Jun 2026: 43.00%Sep 2026: 42.90%43.00%39.50%42.90%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters42.90%43.00%39.50%39.50%
Public57.10%57.00%60.50%60.50%

Charges & borrowings

Open charges
₹827.92 Cr
Satisfied charges
₹5,103.76 Cr
Breakdown by lending institutions
Others₹824.18 Cr
First Blue Home Finance Limited₹2.00 Cr
Axis Bank Limited₹1.70 Cr
Centurian Bank Ltd.₹0.04 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
22 May 2026101309566Others₹1.25 CrOpen
21 May 2026101306320Others₹19 LakhOpen
28 Apr 2026101288839Others₹28.5 LakhOpen
23 Mar 2026101280124Others₹12 LakhOpen
20 Mar 2026101276583Others₹74 LakhOpen

To see the full charge records of Ind Swift Laboratories Limited, buy the company report.

Total charge records: 104 View all charges

Deals & funding

Ind Swift Laboratories Limited has 125 deals on record (110 market trades, 11 funding rounds, 3 convertible or debt financings), with disclosed funding of ₹260.65 Cr; the latest was in May 2026.

Total deals
125
Market trades
110
Funding rounds
11
Convertible or debt financings
3
Secondary share transfer
1
Disclosed funding
₹260.65 Cr

Deals on record (5 of 125)

WhenDealAmountParties
May 2026Market trade₹10.4 CrBuyer: Hrti Private Limited
Seller: Hrti Private Limited
Apr 2026Market trade₹105.47 CrBuyer: Nova Global Opportunities Fund Pcc - Touchstone, Mansi Share and Stock Broking Private Limited , F3 Advisors Private Limited
Seller: Hcp Investments, F3 Advisors Private Limited , Mansi Share and Stock Broking Private Limited
Feb 2026Market trade₹6.41 CrBuyer: NK Securities Research Private Limited
Seller: NK Securities Research Private Limited
May 2025Market trade₹4.47 CrBuyer: an individual
Seller: Wilson Holdings Private Limited
May 2025Market trade₹2.77 CrSeller: Wilson Holdings Private Limited

To see the full deal history of Ind Swift Laboratories Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Ind Swift Laboratories Limited was last rated by Icra on 10 Aug 2020.

Rating agencyRated onRating
Icra10 Aug 2020

To see the full credit ratings and regulatory alerts of Ind Swift Laboratories Limited, buy the company report.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Ind Swift Laboratories Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

Group structure & subsidiaries

Ind Swift Laboratories has 2 subsidiary companies. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

2
Subsidiary companies
Key subsidiaries
Company NameCINShares held
MJM Remedies Private LimitedU24230CH2022PTC044464
Fortune (India) Constructions LimitedU45200CH2005PLC028005

To see the full group structure of Ind Swift Laboratories Limited, buy the company report.

GST

Ind Swift Laboratories has 17 GST registrations: 15 active and 2 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
17
Active
15
Cancelled / inactive
2
GSTINStateStatusRegistered on
04AAACI6306G1Z1ChandigarhActive01 Jul 2017
04AAACI6306G2Z0ChandigarhActive01 Feb 2018
03AAACI6306G1Z3PunjabActive01 Jul 2017
01AAACI6306G1Z7Jammu and KashmirActive08 Jul 2017

To see the full GST registrations and return filing status of Ind Swift Laboratories Limited, buy the company report.

Recent activity

Ind Swift Laboratories Limited has 57 board changes on record since 1995: 33 appointments and 24 cessations. The latest: Prabhat Khurana was appointed as Director on 05 Jul 2025.

Charges
A charge with Others amounted to Rs. 1.25 Cr with Charge ID 101309566 was registered on 22 May 2026.
Charges
A charge with Others amounted to Rs. 0.19 Cr with Charge ID 101306320 was registered on 21 May 2026.
Charges
A charge with Others amounted to Rs. 0.29 Cr with Charge ID 101288839 was registered on 28 Apr 2026.
Filing
Ind Swift Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Chandigarh.
Charges
A charge with Others amounted to Rs. 0.12 Cr with Charge ID 101280124 was registered on 23 Mar 2026.
Charges
A charge with Others amounted to Rs. 0.74 Cr with Charge ID 101276583 was registered on 20 Mar 2026.
Charges
A charge with Others amounted to Rs. 1.55 Cr with Charge ID 101278441 was registered on 19 Mar 2026.
Charges
A charge with Others amounted to Rs. 2.50 Cr with Charge ID 101234523 was registered on 27 Jan 2026.
Charges
A charge with Others amounted to Rs. 1.37 Cr with Charge ID 101223927 was registered on 23 Dec 2025.
AGM
Ind Swift Laboratories Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records.
Appointed
Prabhat Khurana was appointed as Director.
Ceased
Sri Prakash Sharma ceased to be Director.

303 earlier events are in the company report.

News

Frequently asked questions

Ind Swift Laboratories is an active public limited company based in Chandigarh, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 04 January 1995 (31+ years old) and is registered under CIN L24232CH1995PLC015553. Listed on BSE: 532305 and NSE: INDSWFTLAB.

Ind Swift Laboratories reported revenue of ₹641.29 Cr for FY 2025-26 (up 14.2% YoY) based on consolidated financials.

Ind Swift Laboratories has 8 current directors:

The latest financial statements of Ind Swift Laboratories on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 29 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Ind Swift Laboratories is 04AAACI6306G1Z1, registered in Chandigarh. The company has 17 GST registrations in all, of which 15 are active and 2 are cancelled or inactive. Other active GSTINs include 04AAACI6306G2Z0 (Chandigarh), 03AAACI6306G1Z3 (Punjab), 01AAACI6306G1Z7 (Jammu and Kashmir).

The CIN (Corporate Identification Number) of Ind Swift Laboratories is L24232CH1995PLC015553. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Ind Swift Laboratories is a listed company as per MCA records. Its shares are listed on both BSE (code: 532305) and NSE (symbol: INDSWFTLAB).

Ind Swift Laboratories has 354 court cases on record: 87 filed by the company and 268 filed against it. 23 are pending. Most are in the district courts.

Ind Swift Laboratories was incorporated on 04 January 1995, making it 31+ years old. It is registered with the Registrar of Companies, Chandigarh.

Ind Swift Laboratories has 125 deals on record (110 market trades, 11 funding rounds, 3 convertible or debt financings), with disclosed funding of ₹260.65 Cr; the latest was in May 2026.

The peers of Ind Swift Laboratories by revenue are Anuh Pharma Limited, RPG Life Sciences Limited, Ami Lifesciences Pvt Ltd, Nosch Labs Private Limited, Amoli Organics Private Limited and 4 more, all in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).